Roche Holding AG (RHHBY) on Wednesday reported positive results from the phase III lidERA study of giredestrant in oestrogen receptor (ER)-positive early-stage breast cancer. The adjuvant endocrine therapy reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care treatment.
At three years, 92.4% of patients receiving giredestrant were alive and free of invasive disease, versus 89.6% in the control group. The drug also achieved a 31% reduction in the risk of distant recurrence.
"The substantial efficacy observed with giredestrant in the lidERA trial underscores its potential to become a new standard-of-care endocrine therapy in ER-positive early-stage breast cancer, where the chance for cure is highest," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.